Washington Threatens; Wall Street Reacts
This article was originally published in RPM Report
Executive Summary
The biotech investment boom hit the brakes at the end of the first quarter when Rep. Henry Waxman (D-Calif.) publicly complained about Gilead’s pricing for the hepatitis C therapy Sovaldi. The fact that Waxman’s attack has little substantive impact didn’t seem to matter. Another Washington threat—to undo “tax inversion” strategies—is probably much more real, but may actually boost the sector for the rest of 2014.
You may also be interested in...
A New Type of Investor Relations for Biopharma
The biopharma industry is facing strong pressure to justify its pricing practices. And not just from politicians.
A New Type of Investor Relations for Biopharma
The biopharma industry is facing strong pressure to justify its pricing practices. And not just from politicians.
Congressional Dems Generating Heat, But No Hearings, On Rx Prices
House oversight committee Democrats want to subpoena Valeant Pharmaceuticals and hold a hearing with Turing Pharmaceuticals on drug price increases. Their requests may have more impact on investors than committee leadership, as the company saw a same-day stock decrease of 16%.